Intervention

Pomalidomide

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting2

Common conditions15

Lead sponsors shown4

Clinical trials

6 shown

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNCT05389423 · 2023-06-27

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVNCT04902443 · 2021-12-10

Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionNCT03601806 · 2021-04-26

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabNCT04270175 · 2021-04-14

ACTIVE_NOT_RECRUITING

Pomalidomide for Kaposi Sarcoma in People With or Without HIVNCT01495598 · 2012-01-10

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and EtoposideNCT00537511 · 2008-02-01

Common conditions

Kaposi Sarcoma2 AL Amyloidosis1 Amyloid1 B-Cell Neoplasm1 Burkitt Lymphoma1 Carcinoma, Small Cell1 Diffuse Large Cell Lymphoma1 EBV/KSHV-associated Lymphomas1 Human Immunodeficiency Virus 1 Positive1 Non-Hodgkin Lymphoma1 Plasmablastic Lymphoma1 Refractory AL Amyloidosis1 Sarcoma, Kaposi1 Skin Kaposi Sarcoma1 Viral Associated Malignancies1

Leading sponsors

National Cancer Institute (NCI)3 AIDS Malignancy Consortium1 Celgene1 Weill Medical College of Cornell University1

Trial status mix

COMPLETED2

RECRUITING2

ACTIVE_NOT_RECRUITING1

TERMINATED1

Phase mix

PHASE14

PHASE24

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.